Diabetes, metformin, and breast cancer: Lilac time?

Journal of Clinical Oncology

Volumn 30, Issue 23, 2012, Pages 2812-2814

  Goodwin, Pamela J ^a   Thompson, Alastair M ^b   Stambolic, Vuk ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN RECEPTOR; METFORMIN; PROGESTERONE RECEPTOR; SULFONYLUREA DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE ASSOCIATION; EDITORIAL; HUMAN; MAMMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING TEST;

BREAST NEOPLASMS; DIABETES MELLITUS; FEMALE; HUMANS; METFORMIN;

EID: 84865062741     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.3319     Document Type: Editorial

References (41)

1. Giovannucci E, Harlan DM, Archer MC, et al: Diabetes and cancer: A consensus report. Diabetes Care 33:1674-1685, 2010
2. La Vecchia C, Giordano SH, Hortobagyi GN, et al: Overweight, obesity, diabetes, and risk of breast cancer: Interlocking pieces of the puzzle. Oncologist 16:726-729, 2011
3. Gallagher EJ, LeRoith D: Diabetes, cancer, and metformin: Connections of metabolism and cell proliferation. Ann N Y Acad Sci 1243:54-68, 2011
4. Evans JM, Donnelly LA, Emslie-Smith AM, et al: Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305, 2005 (Pubitemid 40813563)
5. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al: Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30:2844- 2852, 2012
6. Liao S, Li J, Wei W, et al: Association between diabetes mellitus and breast cancer risk: A meta-analysis of the literature. Asian Pac J Cancer Prev 12:1061-1065, 2011
7. Bowker SL, Richardson K, Marra CA, et al: Risk of breast cancer after onset of type 2 diabetes: Evidence of detection bias in postmenopausal women. Diabetes Care 34:2542-2544, 2011
8. Carstensen B, Witte DR, Friis S: Cancer occurrence in Danish diabetic patients: Duration and insulin effects. Diabetologia 55:948-958, 2012
9. Belfiore A, Malaguarnera R: Insulin receptor and cancer. Endocr Relat Cancer 18:R125-R147, 2011
10. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029- 1033, 2009
11. Sieri S, Muti P, Claudia A, et al: Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 130:921-929, 2012
12. Goodwin PJ, Ennis M, Pritchard KI, et al: Insulin- and obesity-related variables in early-stage breast cancer: Correlations and time course of prognostic associations. J Clin Oncol 30:164-171, 2012
13. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002 (Pubitemid 34032594)
14. Pasanisi P, Berrino F, De PM, et al: Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119:236-238, 2006
15. Irwin ML, Duggan C, Wang CY, et al: Fasting C-peptide levels and death resulting from all causes and breast cancer: The health, eating, activity, and lifestyle study. J Clin Oncol 29:47-53, 2011
16. Duggan C, Irwin ML, Xiao L, et al: Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 29:32-39, 2011
17. Emaus A, Veierød MB, Tretli S, et al: Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat 121:651-660, 2010
18. Pritchard KI, Shepherd LE, Chapman JA, et al: Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early stage breast cancer in post-menopausal women: NCIC CTG MA.14. J Clin Oncol 29:3869-3876, 2011
19. Lipscombe LL, Goodwin PJ, Zinman B, et al: Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 98:303-309, 2006 (Pubitemid 44195600)
20. Hemkens LG, Grouven U, Bender R, et al: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 52:1732-1744, 2009
21. Currie CJ, Poole CD, Gale EA: The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777, 2009
22. Colhoun HM: Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755-1765, 2009
23. Dejgaard A, Lynggaard H, Rastam J, et al: No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: A metaanalysis. Diabetologia 52:2507-2512, 2009
24. Home PD, Lagarenne P: Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52:2499-2506, 2009
25. Jonasson JM, Ljung R, Talbäck M, et al: Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52:1745-1754, 2009
26. Ljung R, Talbäck M, Haglund B, et al: Insulin glargine use and short-term incidence of malignancies: A three-year population-based observation. Acta Oncol 50:685-693, 2011
27. Gough SC, Belda-Iniesta C, Poole C, et al: Insulin therapy in diabetes and cancer risk: Current understanding and implications for future study- Proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at the Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UK. Adv Ther 28:1-18, 2011 (suppl 5)
28. Bodmer M, Meier C, Krähenbühl S, et al: Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304-1308, 2010
29. Bosco JL, Antonsen S, Sørensen HT, et al: Metformin and incident breast cancer among diabetic women: A population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 20:101-111, 2011
30. Libby G, Donnelly LA, Donnan PT, et al: New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625, 2009
31. Alimova IN, Liu B, Fan Z, et al: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8:909-915, 2009
32. Liu B, Fan Z, Edgerton SM, et al: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8:2031- 2040, 2009
33. Deng XS, Wang S, Deng A, et al: Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 11:367-376, 2012
34. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8:88-96, 2009
35. Dowling RJ, Niraula S, Stambolic V, et al: Metformin in cancer: Translational challenges. J Mol Endocrinol 48:R31-R43, 2012
36. Berstein LM, Boyarkina MP, Tsyrlina EV, et al: More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Med Oncol 28:1260-1263, 2011
37. He X, Esteva FJ, Ensor J, et al: Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol [epub ahead of print on November 22, 2011]
38. Bayraktar S, Hernadez-Aya LF, Lei X, et al: Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118:1202-1211, 2012
39. Hadad S, Iwamoto T, Jordan L, et al: Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783-794, 2011
40. Niraula S, Stambolic V, Dowling RJO, et al: Clinical and biologic effects of metformin in early stage breast cancer. Cancer Res 70:104s, 2010 (suppl 24)
41. Goodwin PJ, Stambolic V, Lemieux J, et al: Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126:215-220, 2011